S-1: ICoreConnect Amends February Purchase Agreements, Increases Offering Size to $8.25 Million

ICoreConnect Inc. amends its February 2024 securities purchase agreements, increasing the offering size to $8.25 million and modifying amortization payment terms.

Summary

• ICoreConnect Inc. has amended its securities purchase agreements from February 26, 2024, with holders of February 2024 Offering Promissory Notes.
• The amendment increases the offering size from $3,300,000 to $8,250,000.
• The company can accelerate amortization payments on both existing and future notes with written notice.
• Holders can voluntarily convert amounts under the First Closing Notes at a conversion price equal to the Market Price.
• The company must file a preliminary information statement on Schedule 14A with the SEC regarding Shareholder Approval by April 30, 2024.
• The initial Registration Statement shall include no less than 6,600,000 shares of Common Stock.
• The company must file a Current Report on Form 8-K describing the terms of the transactions contemplated hereby in the form required by the 1934 Act and attaching the Amendment, to the extent they are required to be filed under the 1934 Act, on or before 9:30 a.m., New York City time, on or prior to the fourth (4th) business day after the date of this Amendment.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company is securing additional funding, which is generally a positive sign. However, the need for shareholder approval and the potential for conversion price adjustments introduce some uncertainty.

Positives

• The company gains flexibility in managing its debt obligations through accelerated amortization payments.
• Holders are given the option to voluntarily convert First Closing Notes at a conversion price equal to the Market Price.
• The company has the requisite corporate power and authority to enter into and consummate the transactions contemplated by this Amendment.

Negatives

• The company is required to file a Current Report on Form 8-K describing the terms of the transactions contemplated hereby in the form required by the 1934 Act and attaching the Amendment, to the extent they are required to be filed under the 1934 Act, on or before 9:30 a.m., New York City time, on or prior to the fourth (4th) business day after the date of this Amendment.

Risks

• Failure to file a preliminary information statement on Schedule 14A with the SEC with respect to the Shareholder Approval on or before April 30, 2024.
• Failure to file a definitive information statement on Schedule 14A with the SEC with respect to the Shareholder Approval as soon as permissible under applicable securities laws after the Pre-14A is filed.
• Failure to obtain the Shareholder Approval within sixty (60) calendar days after the Allocated Exchange Cap Depletion Date.
• Holding any meeting of its shareholders without a proposal for obtaining the Shareholder Approval in such meeting at any time prior to the date that the Shareholder Approval becomes effective pursuant to the rules promulgated under the 1934 Act.

Future Outlook

The company intends to secure the listing or designation for quotation of all additional Common Stock to be issued pursuant to the February 2024 Offering.

Management Comments

• Robert McDermott, CEO, stated the company is pleased to offer modifications to the Transaction Documents.

Industry Context

This announcement reflects ongoing capital market activity within the technology sector, where companies frequently adjust financing terms to optimize capital structure and support growth initiatives.

Comparison to Industry Standards

• Comparable companies in the SaaS space, such as ZoomInfo and HubSpot, often utilize convertible notes as part of their financing strategies.
• The terms of this amendment, including the conversion price and amortization schedule, appear to be within the range of similar transactions in the market.
• The requirement for shareholder approval aligns with Nasdaq listing rules and is a common practice to protect shareholder interests.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of additional shares.
• Note Holders: Modification of amortization payment terms and voluntary conversion options.
• Company: Increased access to capital to fund operations and growth.

Next Steps

• File a preliminary information statement on Schedule 14A with the SEC by April 30, 2024.
• Obtain Shareholder Approval within sixty (60) calendar days after the Allocated Exchange Cap Depletion Date.
• File a Current Report on Form 8-K describing the terms of the transactions contemplated hereby in the form required by the 1934 Act and attaching the Amendment, to the extent they are required to be filed under the 1934 Act, on or before 9:30 a.m., New York City time, on or prior to the fourth (4th) business day after the date of this Amendment.
• Secure the listing or designation for quotation of all of the additional Common Stock to be issued pursuant to the February 2024 Offering.

Key Dates

Keywords

securities purchase agreement, amendment, offering size, amortization payments, voluntary conversion, shareholder approval, registration statement, common stock, ICoreConnect